AMBASSADOR OF TOPX NETWORK



About Cristianne Rijcken | CSO, Cristal Therapeutics & Strategic and CMC Consultant, Liberates

Cristianne Rijcken is the founder of Cristal Therapeutics and serves as Chief Scientific Officer of the company. Dr. Rijcken’s PhD thesis provided a strong basis for Cristal Therapeutics, and she was awarded multiple grants and prizes including the Simon Stevin Gezel Award in 2008 and the Knowledge for Growth Inspiring Young Scientist Award in 2014. She is (co-) author of ~ 50 scientific publications and co-inventor of all patents and patent applications of Cristal Therapeutics. Cristianne is selected as Limburg Businesswoman of the Year 2017 because of her innovative mind-set, the perseverance upon translational activities and her entrepreneurial attitude. Dr. Rijcken is pharmacist by training and holds a PhD degree in Pharmaceutics from Utrecht University (The Netherlands). 

Apart from working as the CSO at Cristal Therapeutics, currently, Cristianne provides as consultant strategic, CMC and translational support to start up companies in life sciences such as TTxD NL BV and Simmunext. She also functions as mentor for Talent Accelerator Program – a talent & mentoring program of eight months in which junior bioBusiness professionals can learn from experienced executives and experts by means of training, coaching and consultative sessions.


About Cristal Therapeutics

Cristal Therapeutics was a clinical stage pharmaceutical company developing the next generation nanomedicines based on its proprietary CriPec® platform to treat various diseases, including cancer. CriPec® is perfectly suited for the development of highly customizable (targeted) nanomedicines with superior efficacy and safety profiles. The most advanced product in development has been CriPec® docetaxel for the treatment of solid tumours. Next to CriPec® docetaxel, the product portfolio comprised various early-stage products in various therapeutic areas. Cristal Therapeutics developed these products independently, as well as in collaboration with third parties. Currently, the main focus is to commercially exploit CliCr® as a next generation class of metal-free click reagents.

For more information: cristaltherapeutics.com

Powered by:
Hyphen Projects BV   

    Connect with us                  

Join TOPX

Privacy Policy
Terms & Conditions 
Chamber of Commerce:
32110979
VAT no: NL8184.34.491.B01

         
  
  
  
                                    

© Copyright 2020 by Hyphen Projects